Combining continuous glucose monitoring with GLP-1 drugs like semaglutide could enable personalized obesity treatment, but no clinical trials have tested this combination in non-diabetic populations.
Zero RCTsDespite growing consumer use of both CGM devices and GLP-1 weight-loss drugs, no randomized controlled trials have evaluated their combined use for obesity in people without diabetes.
What the researchers found
This perspective proposes combining continuous glucose monitoring (CGM) with GLP-1 receptor agonists like semaglutide for personalized obesity management, even in people without diabetes. CGM provides real-time metabolic feedback that could help optimize GLP-1 therapy by tracking glucose variability and behavioral patterns, while GLP-1 drugs address appetite dysregulation and hyperinsulinemia. However, the authors acknowledge a critical evidence gap: no randomized controlled trials have assessed this combination specifically for obesity in non-diabetic populations. They also note that CGM-derived metrics remain unstandardized in this context and suggest that AI-driven CGM analysis could predict individual responsiveness to GLP-1 therapy.
Why it matters
CGM devices are increasingly being marketed directly to consumers for general wellness and weight management, even without diabetes. Simultaneously, GLP-1 drugs are being prescribed to millions of non-diabetic people for weight loss. The convergence of these two trends creates a natural question: could combining real-time glucose data with GLP-1 therapy produce better, more personalized obesity outcomes? This perspective frames the opportunity while honestly noting that evidence to support the combination doesn't yet exist.
The numbers in context
0 RCTs of CGM + GLP-1 RA in non-diabetic obesity · CGM metrics unstandardized for obesity context
How the study worked
This is a narrative perspective reviewing existing evidence on CGM technology, GLP-1 receptor agonist therapy, and the potential synergy between them for obesity management. It synthesizes current knowledge and identifies evidence gaps rather than presenting original data.
Who was studied
Not applicable — perspective article discussing the theoretical combination of CGM and GLP-1 RA for non-diabetic obesity management
What this study cannot tell us
This is an opinion/perspective piece with no original data. The proposed benefits of combining CGM with GLP-1 therapy are theoretical — no clinical trials have tested this approach. CGM metrics in non-diabetic populations lack established reference ranges and clinical significance thresholds. The cost-effectiveness of adding CGM to GLP-1 therapy is not addressed. The perspective doesn't discuss potential harms of CGM in non-diabetic populations, such as anxiety from glucose fluctuations that are actually normal.
How to read the evidence
This is a perspective article presenting a theoretical framework for combining two existing technologies. No original data is presented, and the central proposition (that CGM + GLP-1 RA is better than GLP-1 RA alone for obesity) has not been tested in clinical trials.
When this study was published
Published in 2025, this perspective is timely given the explosive growth of both the CGM wellness market and GLP-1 prescriptions for non-diabetic obesity. The evidence gap it identifies is actively relevant to clinical practice and research priorities.
The bigger picture
The consumer health technology market is pushing CGM into mainstream wellness, while the GLP-1 drug market is rapidly expanding beyond diabetes into general obesity. Both are multi-billion-dollar markets. The idea of combining them is commercially attractive and scientifically plausible — glucose variability data could help clinicians titrate GLP-1 doses, identify non-responders early, and provide patients with behavioral insights. However, the rush to combine these technologies has outpaced the evidence, and this perspective responsibly highlights that gap.
Questions still open
- Does CGM-guided feedback actually improve weight loss outcomes when added to GLP-1 therapy in non-diabetic obesity?
- What CGM-derived metrics are most meaningful for obesity management as opposed to diabetes management?
- Could AI analysis of CGM data predict which patients will respond best to specific GLP-1 drugs or doses?
Common questions
Should I wear a CGM while taking a GLP-1 drug for weight loss?
What could CGM data tell you while on a GLP-1 drug?
Read the original research
Optimising obesity management: integrating continuous glucose monitoring with GLP-1 receptor agonists.
Diabetes research and clinical practice, 228, 112434
Citation
Gupta, Pragati; Pozzilli, Paolo. (2025). Optimising obesity management: integrating continuous glucose monitoring with GLP-1 receptor agonists.. Diabetes research and clinical practice, 228, 112434. https://doi.org/10.1016/j.diabres.2025.112434